Sun Pharma Q2 net up 15% at Rs 1,572 cr

Image
Press Trust of India New Delhi
Last Updated : Nov 13 2014 | 5:00 PM IST
Sun Pharma today said its consolidated net profit rose by 15 per cent to Rs 1,572 crore for the second quarter ended September 30.
The drug major had posted a net profit of Rs 1,362 crore during the same period of previous fiscal.
Net sales of the company rose to Rs 4,751 crore for the second quarter, up 13 per cent, from the same period of previous fiscal, Sun Pharmaceutical Industries said in a filing to the BSE.
"Our Q2 performance was strong and continued to achieve high level of profitable growth, in-line with our expectations, " Sun Pharma Managing Director Dilip Shanghvi said.
The company remains focused on strengthening its existing businesses and developing a differentiated and specialty product basket as well as planning for the Ranbaxy integration, he added.
In a separate filing, the company said its board has approved merger of Sun Pharma Global Inc, a wholly owned foreign subsidiary of the company, with itself, with effect from January 1, 2015.
Sun Pharma shares closed marginally up 0.26 per cent at Rs 908.60 apeice on the BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 13 2014 | 5:00 PM IST

Next Story